TNF alpha immunoconjugate formulations
By expressing in Chinese hamster ovarian CHO cells and using semi-continuous fermentation and multi-step chromatography purification, the problem of glycosylation level control and stability in large-scale production of L19-human TNFα preparation was solved, and biological activity and heat were improved Stability, suitable for industrial production and therapeutic applications.
Patent Information
- Application Number
- CN202380028689.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-21
- Filing Date
- 2023-03-21
- Publication Date
- 2024-11-08
AI Technical Summary
Prior art is difficult to effectively express and prepare L19-human TNFα immunoconjugates for the treatment of human patients in large-scale production, especially while maintaining low glycosylation levels and ensuring biological activity, thermal stability and storage stability. , there are problems of low yield and high immunogenicity.
A production method was designed to control glycosylation levels between 3% and 5.36% by expressing recombinant L19-TNFα in Chinese hamster ovarian CHO cells, using semi-continuous fermentation and multi-step chromatography purification process to ensure non-glycosylation The percentage of L19-TNFα is higher than that of L19-TNFα, which improves the biological activity and stability of the formulation.
The glycosylation level in the L19-TNFα formulation was achieved with a high yield, which improved biological activity and thermal stability, reduced sensitivity to protease-mediated degradation, and was suitable for lyophilization treatment, reducing immunogenicity and Differences between batches, suitable for industrial production.
Smart Images

Figure BDA0005049863760000091 
Figure BDA0005049863760000101 
Figure BDA0005049863760000111
Abstract
Description
[0001] This application claims priority from European patent application No. 22163383.7 filed on March 21, 2022, the contents and elements of which are incorporated herein by reference for all purposes. Technical Field
[0002] The present invention relates to a preparation, particularly a pharmaceutical preparation, comprising a non-glycosylated TNFα immunoconjugate and a glycosylated TNFα immunoconjugate, wherein the percentage of the glycosylated TNFα immunoconjugate in the preparation to the total TNFα immunoconjugate is low, preferably 10% or less. The preparation can be used to treat cancer in human patients, such as brain tumors. Background Art
[0003] The applicants described immunoconjugates comprising human TNFα fused to the antibody L19 ("L19-TNFα") in WO 2001 / 062298 (hereby incorporated by reference in its entirety). L19 (U.S. Pat. No. 8,097,254) specifically binds to the ED-B domain of the fibronectin isoform B-FN, one of the best-known markers of angiogenesis. ED-B is an additional domain of 91 amino acids found in the B-FN isoform. ED-B accumulates around new vascular structures in invasive tumors and other tissues undergoing angiogenesis (such as the endometrium in the proliferative phase and some ocular structures in pathological conditions), but is otherwise undetectable in normal adult tissues. The applicant has previously described a number of uses (including the treatment of human cancer) and formulations of L19-TNFα in WO 2013 / 045125, WO 2018 / 011404, WO 2019 / 185792, WO 2021 / 234178 (incorporated herein by reference in their entireties).
[0004] Large-scale production of immunoconjugates (such as L19-TNFα) can be achieved by recombinant expression. However, prokaryotic (bacterial) expression is not suitable for expressing complex proteins such as L19-TNFα, which forms a large 150 kDa non-covalent homotrimer in solution.
[0005] Borsi et al. Blood (2003) 102, 4384 described in detail a method for expressing recombinant L19-murine (m)TNFα using SP2 / 0 murine myeloma cells, reporting a final yield of 3 mg / L of purified protein, which is not suitable for industrial production of conjugates.
[0006] In view of the foregoing, there is a need in the art for additional methods for large-scale production of L19-human TNFα suitable for treating human patients. Summary of the invention
[0007] The inventors have devised a production process for preparing L19-TNFα which has a high yield and surprisingly results in a low percentage of glycosylated L19-TNFα in the preparation. In particular, the percentage of glycosylated L19-TNFα in the preparation is reported to be between 3% and 5.36% ( Figure 5A ), an average of 4.19% of the L19-TNFα was glycosylated ( Figure 5B ).
[0008] In addition, it is expected that formulations containing a low percentage of glycosylated L19-TNFα have superior biological activity compared to formulations containing a high percentage of glycosylated L19-TNFα. In particular, it is expected that the non-glycosylated L19-TNFα conjugate has increased affinity for tumor necrosis factor receptor 1 (TNFR1) and / or tumor necrosis factor receptor 2 (TNFR2) relative to the glycosylated L19-TNFα conjugate.
[0009] It is also expected that formulations containing a low percentage of glycosylated L19-TNFα have superior thermal stability and / or storage stability compared to formulations containing a high percentage of glycosylated L19-TNFα. In particular, it is expected that non-glycosylated L19-TNFα conjugates have increased thermal stability relative to glycosylated L19-TNFα conjugates.
[0010] Still further, it is expected that formulations containing a low percentage of glycosylated L19-TNFα are less susceptible to protease-mediated degradation than formulations containing a high percentage of glycosylated L19-TNFα. In particular, it is expected that non-glycosylated L19-TNFα conjugates are less susceptible to protease-mediated degradation relative to glycosylated L19-TNFα conjugates.
[0011] It is also expected that formulations containing a low percentage of glycosylated L19-TNFα will be more suitable for lyophilization than formulations containing a high percentage of glycosylated L19-TNFα.
[0012] Without wishing to be bound by theory, it is believed that the fermentation conditions used to prepare the L19-TNFa conjugates described herein result in the low levels of glycosylated species observed.
[0013] High levels of glycosylation pose challenges in terms of batch-to-batch reproducibility for good manufacturing practice (GMP) production, increased immunogenicity, and suboptimal pharmacokinetics when preparing products for industrial development. Durocher and Butler, Current Opinion Biotechnol (2009), 20, 770 explain that glycan structures may be immunogenic, and immunogenicity may reduce the efficacy of biologics due to rapid clearance by the immune system. Planinc et al., Analytica Chimica Acta (2016) 13, 27 similarly confirm the importance of low abundance of glycans due to their potential immunogenicity. Leepenies and Seeberger Nature Biotechnol. (2016), 32, 443 further comment that heterogeneous glycosylation may lead to batch-to-batch differences in efficacy or pharmacokinetics.
[0014] In view of the disadvantages associated with glycosylation of immunoconjugates such as L19-TNFα described in detail above, it is expected that the low percentage of glycosylated L19-TNFα in the preparations produced by the production method designed by the inventors will have advantageous properties when used for the treatment of human patients, compared to L19-TNFα preparations containing a higher percentage of glycosylated L19-TNFα.
[0015] The low level of glycosylated L19-TNFα in the preparation is unexpected in view of the fact that it has been previously shown that the production of human TNFα results in high levels of glycosylation when prepared in the same cell line (Chinese hamster ovary). In particular, in WO98 / 55662, the expression of recombinant non-conjugated human TNFα in Chinese hamster ovary (CHO) cells resulted in the following TNFα preparation, in which 35% of the total TNFα was reported to be O-glycosylated. The authors believe that this is advantageous because glycosylated TNFα can have an increased half-life in body fluids, can improve binding to receptors, and can be better protected against the effects of proteases compared to non-glycosylated TNFα. In Takakura et al., Eur J Bioch (1996), 235, 431, the human B cell lymphoblastoid cell line BALL-1 was used to express recombinant human TNFα. Consistent with the high levels of glycosylation reported in WO 98 / 55662, the percentage of O-glycosylated TNFα in the resulting preparation was reported to be 20%. It was further reported that O-glycosylation is linked to the serine at position 4 of the amino acid sequence of human TNFα.
[0016] Therefore, in a first aspect, the present invention provides a formulation comprising:
[0017] (i) a non-glycosylated TNFα immunoconjugate; and
[0018] (ii) glycosylated TNFα immunoconjugate;
[0019] wherein the TNFα immunoconjugate comprises human TNFα conjugated to an antibody molecule containing the L19 complementarity determining region (CDR) shown in SEQ ID NOs: 1 to 6, and
[0020] The percentage of the glycosylated TNFα immunoconjugate in the preparation is ≤10% of the total TNFα immunoconjugate.
[0021] In a preferred embodiment, the antibody molecule in the TNFα immunoconjugate comprises the L19 VH domain shown in SEQ ID NO: 7 and the L19 VL domain shown in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv form shown in SEQ ID NO: 10. Most preferably, the TNFα immunoconjugate consists of or comprises the sequence of L19-TNFα shown in SEQ ID NO: 13.
[0022] The TNFα is preferably human TNFα.Most preferably, the TNFα has the sequence shown in SEQ ID NO:11.
[0023] Therefore, in a preferred embodiment, the present invention provides a preparation comprising:
[0024] (i) non-glycosylated L19-TNFα; and
[0025] (ii) glycosylated L19-TNFα;
[0026] wherein the L19-TNFα comprises or consists of the sequence shown in SEQ ID NO: 13; and
[0027] The percentage of glycosylated L19-TNFα in the total L19-TNFα in the preparation is ≤10%.
[0028] The percentage of glycosylated TNFα immunoconjugate to total TNFα immunoconjugate in the formulation is preferably ≤10%, ≤9%, ≤8%, ≤7% or ≤6%, with lower glycosylation % being preferred for the reasons explained above.
[0029] The percentage of the glycosylated TNFα immunoconjugate to the total TNFα immunoconjugate in the formulation may be ≥ 2% or ≥ 3%.
[0030] For example, the percentage of the glycosylated TNFα immunoconjugate to the total TNFα immunoconjugate in the formulation may be ≥ 3% and ≤ 6%.
[0031] The glycosylated TNFα immunoconjugate preferably comprises O-linked glycosylation at serine at position 4 of TNFα, wherein the TNFα has the sequence shown in SEQ ID NO: 11. In the case where the TNFα immunoconjugate is L19-TNFα and comprises or consists of the sequence shown in SEQ ID NO: 13, the glycosylated L19-TNFα preferably comprises O-linked glycosylation on serine at position 257 of SEQ ID NO: 13. The O-linked glycosylation preferably comprises a core of a hexose-acetyl-hexose 1 and an N-acetylneuraminic acid residue. Most preferably, the O-linked glycosylation is HexNAc1Hex1NeuAc1. In a preferred embodiment, the TNFα immunoconjugate is not glycosylated at any other position in the TNFα sequence.
[0032] In a preferred embodiment, the present invention provides a preparation comprising:
[0033] (i) non-glycosylated L19-TNFα; and
[0034] (ii) glycosylated L19-TNFα;
[0035] wherein the L19-TNFα comprises or consists of the sequence shown in SEQ ID NO: 13, wherein the percentage of glycosylated L19-TNFα in the total L19-TNFα in the preparation is ≤ 6%, and
[0036] The preparation has higher biological activity than a preparation in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the preparation is 15% or more.
[0037] In a preferred embodiment, the formulation has increased affinity for tumor necrosis factor receptor 1 (TNFR1) and / or tumor necrosis factor receptor 2 (TNFR2) relative to formulations in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the formulation is 15% or more.
[0038] In a preferred embodiment, the formulation has excellent thermal stability and / or storage stability compared to a formulation in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the formulation is 15% or more.
[0039] In preferred embodiments, the formulation is less susceptible to protease-mediated degradation than formulations in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the formulation is 15% or more.
[0040] In a preferred embodiment, the formulation is more suitable for lyophilization than a formulation in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the formulation is 15% or more.
[0041] Methods for determining the type and percentage of glycosylated TNFα immunoconjugate in a preparation of TNFα immunoconjugate are known to those of skill in the art and include mass spectrometry, particularly intact mass analysis, as described herein.
[0042] In addition to the active ingredient (glycosylated and non-glycosylated TNFα immunoconjugates), the pharmaceutical preparations of the present invention may further comprise pharmaceutically acceptable excipients, carriers, buffers, stabilizers or other materials well known to those skilled in the art and suitable for administration to human patients. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. For injection at the tumor site, the pharmaceutical preparations may be in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has a suitable pH, isotonicity and stability.
[0043] The pharmaceutical preparation of the present invention can be used for use in a method for treating cancer in a patient. A method for treating cancer is also provided, the method comprising administering a therapeutically effective amount of the pharmaceutical preparation of the present invention to the patient. Similarly, the use of the pharmaceutical preparation of the present invention in the manufacture of a medicament for treating cancer is provided. The patient is preferably a human patient.
[0044] Cancers that may be treated using the pharmaceutical formulations of the invention include skin cancer (eg, malignant melanoma or non-melanoma skin cancer), sarcomas (eg, soft tissue sarcomas), and brain tumors (eg, gliomas or glioblastomas).
[0045] The present invention includes any combination of the described aspects and preferred features unless such a combination is expressly impermissible or explicitly avoided. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings, in which:
[0047] Figure 1 A general overview of the L19-TNFα production process for obtaining a pharmaceutical preparation of the invention comprising a low percentage of glycosylated L19-TNFα is shown.
[0048] Figure 2The general fermentation procedure for the L19-TNFα production process for obtaining the pharmaceutical preparation of the present invention comprising a low percentage of glycosylated L19-TNFα is shown.
[0049] Figure 3A and Figure 3B : Two-dimensional SDS-PAGE analysis of a pharmaceutical preparation containing a low percentage of glycosylated L19-TNFα confirmed the purity of the post-production sample and the molecular weight (about 45 KDa) and isoelectric point (about 7.7) of L19-TNFα. Two spots are visible: non-glycosylated L19-TNFα (spot 1) and glycosylated L19-TNFα (spot 2). Non-glycosylated L19-TNFα is the most obvious spot, while the spot corresponding to glycosylated L19-TNFα is almost invisible, indicating that the abundance of glycosylated species is very low. Figure 3C : Milligrams of purified L19-TNFα per liter of fermentation culture recovered from seven production batches.
[0050] Figure 4 Deconvoluted spectra of mass spectrometry analysis of L19-TNFα preparations containing a low percentage of glycosylated L19-TNFα prepared according to the methods described herein are shown. The main peak (1) at 43957 Da corresponds to the non-glycosylated L19-TNFα conjugate, while the peak (2) at 44613 Da corresponds to the L19-TNFα variant with O-linked glycosylation at position 257. The other minor peaks are irrelevant: the small peak at 43913 Da is a typical MS artifact, corresponding to L19-TNFα without a CO2 group. Another small peak at 44056 Da corresponds to L19-TNFα aggregated with the phosphate groups of the buffer.
[0051] Figure 5A The percentage of non-glycosylated L19-TNFα and glycosylated L19-TNFα in total L19-TNFα in different production batches of drug formulations prepared using the methods described herein are shown. In seven production batches using the methods described herein, glycosylated L19-TNFα in the formulation never exceeded 6% of the total L19-TNFα, and the average percentage of glycosylated L19-TNFα in the formulation was 4.19% ( Figure 5B ).
[0052] Figure 6The MS1 spectrum of the glycosylated TNFα peptide SSSRTPSDKPVAHVVANPQAEGQLQWLNR in a representative production batch of L19-TNFα formulation containing a low percentage of glycosylated L19-TNFα is shown. The 4+ charged ion detected at 958.21 m / z is consistent with the presence of an additional NeuAc group on the HexNAcHex1 core attached to the serine at position 2 of the TNFα peptide (corresponding to the serine at position 257 in the L19-TNFα conjugate).
[0053] Figure 7 The MS2 spectrum of the glycosylated TNFα peptide SSSRTPSDKPVAHVVANPQAEGQLQWLNR in a representative production batch of L19-TNFα preparations containing a low percentage of glycosylated L19-TNFα is shown. The precursor ion at 958.21 m / z has been isolated and HCD has been fragmented to generate this MS2 spectrum. Together with the expected y-ion list, the presence of two peaks at 274.09 m / z (NeuAc-H2O) and 292.10 m / z (NeuAc) confirms the presence of the NeuAc group on the peptide. The data further confirms the correct identification of the HexNAc1Hex1NeuAc1 group on the serine at position 2 of the peptide (corresponding to the serine at position 257 of the L19-TNFα conjugate). DETAILED DESCRIPTION
[0054] Various aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Other aspects and embodiments will be clear to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
[0055] The pharmaceutical composition of the present invention comprises a TNFα immunoconjugate, wherein the TNFα immunoconjugate comprises an antibody molecule comprising the L19 complementarity determining region (CDR) shown in SEQ ID NOs: 1 to 6 and TNFα.
[0056] The antibody molecule is preferably monoclonal.The antibody molecule may be human or humanized, but is preferably a human antibody molecule.
[0057] The TNFα immunoconjugate may be isolated in the sense of being free of contaminants such as antibodies and / or serum components that are capable of binding to other polypeptides.
[0058] The antibody molecule may be natural or partially or completely synthetically produced. For example, the antibody molecule may be a recombinant antibody molecule.
[0059] The antibody molecule can be an immunoglobulin or an antigen binding fragment thereof. For example, the antibody molecule can be an IgG, IgA, IgE or IgM molecule, preferably an IgG molecule, such as an IgG1, IgG2, IgG3 or IgG4 molecule, but more preferably an antigen binding fragment thereof. In a more preferred embodiment, the antibody molecule comprises or consists of a single-chain Fv (scFv), a small immunoprotein, a diabody, but most preferably an scFv.
[0060] The antibody molecule preferably comprises the L19 VH domain shown in SEQ ID NO: 7 and / or the L19 VL domain shown in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv form shown in SEQ ID NO: 10.
[0061] In the case where the antibody molecule is a scFv, the VH and VL domains of the antibody are preferably connected by a linker of 12 to 20 amino acids. For example, the VH and VL domains can be connected by an amino acid linker of 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length. Suitable linker sequences are known in the art and include the linker sequence shown in SEQ ID NO:8.
[0062] Preferably, TNFα is human TNFα.Most preferably, TNFα comprises or consists of the sequence shown in SEQ ID NO:11.
[0063] The antibody molecule (e.g., in the form of scFv) and TNFα can be directly linked to each other, for example, by any suitable chemical bond, but preferably via a peptide linker. The chemical bond can be, for example, a covalent bond or an ionic bond. Examples of covalent bonds include peptide bonds (amide bonds) and disulfide bonds.
[0064] In the case where TNFα is connected to an antibody molecule via a peptide linker, the peptide linker can be a short (2-30, preferably 10-20) residue stretch of amino acids. Suitable examples of peptide linker sequences are known in the art. One or more different linkers can be used. An exemplary linker sequence is shown in SEQ ID NO: 12. In one embodiment, the linker can be a cleavable linker.
[0065] In case the antibody molecule and TNFα are linked via a peptide bond or a peptide linker, the conjugate can be produced (secreted) as a single-chain polypeptide (eg, a fusion protein).
[0066] In a preferred embodiment, TNFα is conjugated to the C-terminus of an antibody molecule in the form of a scFv.Most preferably, the TNFα immunoconjugate consists of or comprises the sequence of L19-TNFα as shown in SEQ ID NO:13.
[0067] The TNFα in the glycosylated TNFα immunoconjugate contained in the pharmaceutical formulation of the present invention preferably comprises O-linked glycosylation on the serine at position 4 of the TNFα sequence shown in SEQ ID NO: 11. In case the TNFα immunoconjugate is L19-TNFα and comprises or consists of the sequence shown in SEQ ID NO: 13, the glycosylated L19-TNFα preferably comprises O-linked glycosylation on the serine at position 257 of SEQ ID NO: 13.
[0068] The O-linked glycosylation comprises a core of hexose-acetyl-hexose 1 and an N-acetylneuraminic acid residue. Preferably, the O-linked glycosylation is HexNAc1Hex1NeuAc1. In a preferred embodiment, the TNFα immunoconjugate is not glycosylated at any other position in the TNFα sequence.
[0069] The L19 in the glycosylated L19-TNFα immunoconjugate contained in the pharmaceutical formulation of the present invention is non-glycosylated. That is, only the TNFα in the glycosylated L19-TNFα immunoconjugate contained in the pharmaceutical formulation of the present invention is glycosylated.
[0070] The percentage of glycosylated TNFα immunoconjugate to total TNFα immunoconjugate in the pharmaceutical preparation is preferably ≤10%, ≤9.5%, ≤9%, ≤8.5%, ≤8%, ≤7.5%, ≤7%, ≤6.5%, ≤6% or ≤5.5%, with lower glycosylation % being preferred for the reasons explained above. In a preferred embodiment, the glycosylated % is ≤6%, more preferably ≤5.5%.
[0071] The percentage of glycosylated TNFα immunoconjugate to total TNFα immunoconjugate in the formulation may be ≥2%, ≥2.5% or ≥3%. This does not include TNFα immunoconjugates prepared in bacterial cells, which are non-glycosylated.
[0072] For example, the percentage of glycosylated TNFα immunoconjugate to total TNFα immunoconjugate in the formulation may be ≥2% and ≤10%, ≥2% and ≤6%, ≥3% and ≤6%, ≥2% and ≤5.5%, ≥3% and ≤5.5%.
[0073] Methods for measuring the percentage of glycosylated TNFα immunoconjugates present in a pharmaceutical composition and determining the type of glycosylation present are known in the art and include mass spectrometry, particularly intact mass analysis. Exemplary methods are described in detail in Example 3. The results of the analysis are shown in Figures 4 to 7 middle.
[0074] As described in the claims, in addition to glycosylated and non-glycosylated TNFα immunoconjugates, the pharmaceutical formulations of the present invention may include pharmaceutically acceptable excipients, carriers, buffers, stabilizers or other materials known to those skilled in the art and suitable for administration to human patients. The pharmaceutical composition may include a buffer composition as disclosed in WO 2018 / 011404. In particular, the pharmaceutical composition may include glycosylated and non-glycosylated TNFα immunoconjugates and stabilizers dissolved in a sodium phosphate buffer as described in the claims, the sodium phosphate buffer comprising a salt concentration of at least about 1.5 mM, a polysorbate concentration of at least about 0.005% (v / v), wherein the pH of the sodium phosphate buffer is higher than 7.5 and lower than 9. Preferably, the polysorbate concentration is about 0.1% (v / v) or less. The sodium phosphate buffer preferably contains about 0.5%-1.5% w / v of glycerol. The sodium phosphate buffer may further contain NaH2PO4 at a concentration of about 5-25 mM. The sodium phosphate buffer may further comprise Na2HPO4 at a concentration of about 5-20 mM. The sodium phosphate buffer may also comprise KCl at a concentration of about 1-2 mM. In addition, the sodium phosphate buffer may comprise EDTA at a concentration of about 1-20 mM. The stabilizer may be a sugar, preferably mannitol, trehalose, sucrose, sorbitol, maltose or xylitol, most preferably mannitol. The sugar may be present at a concentration of 20-250 mM. The salt may be NaCl and may be present in the sodium phosphate buffer at a concentration of about 10-30 mM. The sodium phosphate buffer preferably comprises polysorbate at a concentration of about 0.005% to about 0.03%. The polysorbate may be polysorbate 20. In a preferred embodiment, the concentration of total TNFα immunoconjugates (glycosylated and non-glycosylated) in the pharmaceutical preparation may be at least about 0.2 mg / mL, more preferably at least about 0.4 mg / mL. In a most preferred embodiment, in addition to glycosylated and non-glycosylated TNFα immunoconjugates, the pharmaceutical formulation of the present invention also contains NaH2PO4 (2H2O) at a concentration of 15mM, Na2HPO4 (2H2O) at a concentration of 10mM, KCl at a concentration of 1.5mM, mannitol at a concentration of 75mM, NaCl at a concentration of 30mM, 1% w / v glycerol, EDTA at a concentration of 5mM, 0.01% v / v Tween20, and has a pH of 8.00.
[0075] The formulations of the present invention are expected to have greater biological activity than formulations in which the percentage of glycosylated L19-TNFα to total L19-TNFα in the formulation is 15% or more, 20% or more, 25% or more, or 30% or more.
[0076] In one embodiment, the formulation is expected to have a higher affinity for TNFRl and / or TNFR2 as measured by BiaCore or other suitable technology.
[0077] In some embodiments, the pharmaceutical formulations of the present invention may be administered alone or in combination with other therapies, either simultaneously or sequentially, depending on the condition to be treated.
[0078] Treatments involving the pharmaceutical preparations of the present invention may include administering a second anticancer therapy. Many suitable anticancer therapies are known in the art. For example, when administered in combination with doxorubicin, dacarbazine, radiotherapy, and temozolomide or lomustine, L19-TNFα has been successfully used in anticancer therapy (WO 2021 / 234178). Clinical trials of these combinations are ongoing. The promising anticancer effects of the combined administration of L19-TNFα and L19-IL2 have also been reported (WO 2018 / 011404). This is a supplement to the anticancer effects shown by L19-TNFα monotherapy.
[0079] Thus, the pharmaceutical formulation of the present invention can be used for use in a method of treating cancer in a patient, wherein the method further comprises administering to the patient a second anticancer therapy selected from the group consisting of doxorubicin, dacarbazine, radiation therapy, and temozolomide, lomustine, or L19-IL2. Administration of the pharmaceutical formulation of the present invention and the second anticancer therapy to the patient can be simultaneous or sequential, wherein simultaneous administration refers to administration in the same treatment cycle but not necessarily on the same day.
[0080] The pharmaceutical formulation of the invention and the second anticancer therapy may be provided as a combined formulation, but are preferably provided as separate formulations to allow simultaneous or sequential administration. Where the treatment further involves radiotherapy, the radiotherapy will have to be administered separately from the pharmaceutical formulation of the invention, but administration may still be simultaneous.
[0081] Other treatments that may be used in combination with the pharmaceutical formulations of the invention include administration of appropriate doses of pain relief drugs such as nonsteroidal anti-inflammatory drugs (eg, aspirin, acetaminophen, ibuprofen, or ketoprofen) or opioids such as morphine or antiemetics.
[0082] In the case of using the pharmaceutical preparation of the present invention for cancer treatment, it can be injected parenterally. In one embodiment, the pharmaceutical preparation of the present invention is injected at the tumor site, preferably by intratumoral injection. Peritumoral injection (e.g., local intradermal injection) is another suitable method for local administration of the pharmaceutical preparation of the present invention to the tumor site. In some embodiments, the pharmaceutical preparation of the present invention can be used by infusion (e.g., intravenous infusion).
[0083] Cancer treatment according to the present invention may include complete eradication of a tumor. The disappearance of any evidence of a significant tumor after termination of treatment indicates complete treatment of the tumor. The disappearance of a tumor may be determined when the tumor has no discernible volume or is no longer visible. Treatment may include treatment that eradicates the tumor and prevents tumor regrowth.
[0084] After administration of the pharmaceutical preparation of the present invention, the patient is preferably monitored during a follow-up period of at least one month, preferably at least six months or at least one year. During the follow-up period, the disappearance of the tumor and the lack of tumor regrowth can be observed. The absence of tumor regrowth can be observed.
[0085] The amount of L19-TNFα administered by administering the pharmaceutical preparation of the present invention to the patient will depend in particular on the size and nature of the tumor. The determination of a suitable dosage is within the capabilities of a skilled practitioner. Suitable dosages are disclosed in WO2021 / 234178, WO 2018 / 011404, and WO 2013 / 045125. In particular, L19-TNFα can be administered in a dosage of 5 to 20 μg / Kg, preferably between 6 and 18 μg / Kg, between 7 and 17 μg / Kg, or between 8 and 15 μg / Kg, more preferably between 10 and 13 μg / Kg. Preferably, the dosage of L19-TNFα is in the range of 200 μg to 400 μg. Most preferably, the dosage of L19-TNFα is 400 μg. These are examples only, and different dosages can be used.
[0086] The pharmaceutical preparation of the present invention can be used for use in a method for treating cancer. The cancer can be a solid tumor. In a preferred embodiment, the cancer is selected from skin cancer (such as malignant melanoma, non-melanoma skin cancer (such as basal cell carcinoma (BCC), squamous cell carcinoma (cSCC))), glioma (such as glioblastoma) or sarcoma (such as soft tissue sarcoma). The cancer can be metastatic or non-metastatic. The cancer can be recurrent or non-recurrent, such as recurrent glioblastoma.
[0087] In the case where the cancer to be treated with the pharmaceutical preparation of the present invention is a glioma (such as a glioblastoma), the pharmaceutical preparation is preferably administered with lomustine and optionally another chemotherapy. The details of this therapy are disclosed in WO 2021 / 234178, which is hereby incorporated by reference in its entirety. Therefore, the pharmaceutical preparation of the present invention can be used in a method for treating a patient's glioma (such as a glioblastoma), wherein the method further comprises administering lomustine and an optional second chemotherapy (such as temozolomide) to the patient.
[0088] In the case where the cancer to be treated with the pharmaceutical preparation of the present invention is skin cancer, the pharmaceutical preparation is preferably administered together with L19-IL2. L19-IL2 preferably comprises or consists of the sequence shown in SEQ ID NO: 14. The details of this therapy are disclosed in WO 2013 / 045125, which is hereby incorporated by reference in its entirety. Therefore, the pharmaceutical preparation of the present invention can be used in a method for treating a patient's skin cancer (such as malignant melanoma or non-melanoma skin cancer, but preferably malignant melanoma), wherein the method further comprises administering L19-IL2 to the patient. It can be administered by injection at the tumor site (particularly by intratumoral injection). Most preferably, the dose of L19-IL2 is 2.17 mg. The dose of L19-IL2 can alternatively be expressed in international units (IU). 2.17 mg L19-IL2 is equivalent to 13 million IU L19-IL2. In the case of intratumoral injection, 13 million IU of L19-IL2 (corresponding to 2.17 mg of L19-IL2) and 400 μg of L19-TNFα once a week can be used to treat patients for one to four weeks (e.g., for one, two, three or four consecutive weeks). The dose can be administered as a single intratumoral injection, or the dose can be divided into multiple intratumoral injections (administered to the same tumor). Alternatively, in some cases, the dose can be halved to 1.08 mg of L19-IL2 and 200 μg of L19-TNFα.
[0089] The features disclosed in the foregoing description, or the attached claims, or the drawings are expressed in their specific forms or in terms of means for performing the disclosed functions, or methods or processes for obtaining the disclosed results, and may be used alone or in any combination of such features as appropriate to implement the present invention in its diverse forms.
[0090] Although the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be clear to those skilled in the art when this disclosure is given. Therefore, the exemplary embodiments of the present invention described above are considered to be illustrative rather than restrictive. Various changes may be made to the described embodiments without departing from the spirit and scope of the present invention.
[0091] For the avoidance of any doubt, any theoretical explanations provided herein are intended to improve the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.
[0092] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0093] Throughout the specification, including the following claims, unless the context requires otherwise, the words "comprise" and "include", and variations such as "comprises", "comprising" and "including", will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.
[0094] It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by using the antecedent "about", it will be understood that the particular value forms another embodiment. The term "about" in relation to a numerical value is optional and means, for example, + / - 10%.
[0095] Example
[0096] Example 1 - Method for producing a L19-TNFα preparation containing a low percentage of glycosylated L19-TNFα
[0097] 1.1 General Description of the Manufacturing Process and Process Control
[0098] L19-TNFα is a recombinant fusion protein stably expressed in Chinese hamster ovary host cells (CHO-K1), which are cultured in bioreactors using a semi-continuous fermentation method. L19-TNFα is recovered from the harvested culture medium through several chromatographic purification steps. The manufacturing process of L19-TNFα API can be divided into two upstream stages and two downstream stages.
[0099] – Upstream 1 (Phase A): Inoculum preparation
[0100] – Upstream 2 (Phase B): Fermentation
[0101] – Downstream 1 (Phase C): Capture purification by affinity chromatography
[0102] - Downstream 2 (Stage D): polishing and formulation by: gel filtration, cation exchange chromatography, buffer exchange, anion exchange chromatography, nanofiltration and final concentration.
[0103] The two upstream stages are dedicated to cell culture, while the downstream stage is used to recover L19-TNFα from the harvested culture medium by chromatographic purification. Figure 1 A process flow diagram summarizing the production of L19-TNFα is shown. The upstream and downstream processes are reported below.
[0104] 1.1.1 Upstream Process
[0105] The upstream process for producing L19-TNFα can be divided into two phases: Upstream 1 (Phase A; inoculum preparation) and Upstream 2 (Phase B; fermentation). Both phases can be divided into several steps:
[0106]
[0107]
[0108]
[0109]
[0110] Upstream 1 (Phase A)
[0111] EX-CELL CD CHO medium with 6 mM L-glutamine (supplied by SAFC, a division of Sigma Aldrich; Cat. No. 14361C-1000ML) allows the cultivation or adaptation of recombinant CHO cells in small scale (flasks). This medium is used in the upstream 1 stage and is supplemented with 20 mM HEPES buffer when used in roller bottles.
[0112] Upstream 2 (Phase B)
[0113] In the upstream 2 stage, EX-CELL CD CHO medium with 6mM L-glutamine was also used for larger scale bioreactor fermentation. In addition, in the upstream 2 stage, the feed supplement BalanCD CHO feed 3 was added to the cell culture of L19-TNFα. In addition, when the glucose concentration dropped below 2g / L, a glucose 30% w / v solution was added to the cell culture to reach a glucose concentration of 4g / L.
[0114] Upstream 1 (Phase A): Inoculum preparation for fermentation
[0115] L19-TNFα cell culture begins with the thawing of the master cell bank vial suitable for L19-TNFα production.First, under standard conditions (37°C, 5% CO2), cell culture is expanded in a T75 / T150 square flask containing 15 / 30ml cell culture, and then expanded in a 2L roller bottle (37°C, 1.2rpm) containing 250ml cell culture. Square flask cell culture is carried out using EX-CELL CD CHO culture medium supplemented with 6mM glutamine (6-XF). For cell culture in roller bottles, the same culture medium supplemented with 20mM HEPES buffer (6-XRG) is used. The cell culture in the square flask and roller bottle is divided every 3-4 days, as described in detail below. Amplify at different dilutions to reach a viable cell concentration in the range of 100.000-150.000 cells / ml after dilution with fresh culture medium. To obtain cell inoculum for bioreactor fermentation, roller bottle cultures were expanded to a total volume of 9 L (36 roller bottles) and a cell concentration of ≥500.000 cells / ml and a viability of ≥60%.
[0116]
[0117] At the end of expansion, the cell suspension was transferred to a sterile bag using a peristaltic pump. The sealed bag was then connected to the bioreactor using a steam-in-place stainless steel connector.
[0118] Upstream 2 (Phase B): Fermentation
[0119] Fermentation is carried out in Biostat C 30 bioreactor (B.Braun). The bioreactor is equipped with a gas mixer and annular sprinkler aeration system with 4 outlets. pH is controlled by CO2 flow and calibrated by adding sodium carbonate solution. The agitator is a single marine impeller. Temperature is controlled by a water jacket connected to a steam heat exchanger. The working volume is 30L, and the total volume of the container is 42L. When a part of the cell culture obtained at the end of the upstream 1 stage is added to the fresh culture medium (inoculum) in the bioreactor, the semi-continuous fermentation process begins. According to the viability and production requirements of the cell culture, the fermentation of a single batch may require 27-48 days. Two paired bioreactors Biostat C 30 are used to ferment in a semi-continuous method, wherein each bioreactor is divided every 6-7 days to harvest cell culture. The volume harvested depends on the viable cell concentration determined before harvesting. To start each new fermentation cycle with a viable cell concentration of 100.000-200.000 cells / ml, enough cell culture was kept in the bioreactor to reach a final working volume of 27 L by adding fresh medium. When the process was carried out in two paired Biostat C 30 reactors, both bioreactors were inoculated in parallel with parts of the cell culture obtained at the end of upstream 1, and semi-continuous fermentations were run simultaneously. The general fermentation protocol is outlined in Figure 2 The operating steps of the upstream 2 (stage B) process are summarized as follows.
[0120]
[0121]
[0122] 1 Steps U2-410 to U2-655 are performed according to the viability of the cell culture and the production requirements. Thus, the fermentation in the bioreactor can be terminated after the 3rd, 4th, 5th or 6th harvest.
[0123] Inoculation of bioreactor
[0124] At the beginning of fermentation, the bioreactor inoculum reaches a viable cell concentration within the range of 100.000-200.000 viable cells / ml. The necessary dilution of the culture medium and cell culture is calculated to reach a total working volume of 27L. Before inoculation, the required amount of culture medium (EX-CELL CHO culture medium + 6mM glutamine) is aseptically filled to the bioreactor. The culture medium is transferred to the bioreactor container by the addition port device of the in situ steam sterilization and passed through a 0.22 μm filter with the help of a peristaltic pump. The required amount of cell culture (approximately corresponding to 1 / 4 of the total fermentation volume) is then inoculated into the bioreactor container to start the fermentation process. The aseptic addition of the inoculum is carried out by gravity through the addition port device of the in situ steam sterilization of the bioreactor.
[0125] Fermentation temperature
[0126] The temperature was maintained at 37°C ± 0.01°C during the entire fermentation process.
[0127] Culture pH
[0128] During the fermentation, the culture pH was kept stable at a pH of 7.20 ± 0.02 by a CO2 flow (partial pressure: 1.25 atm) for acid correction and by calibrated addition of a 20% w / v Na2CO3 solution for alkalinity correction. Acid or base addition was automatically regulated by the bioreactor management software via a gas mixer device (CO2 addition) and a system peristaltic pump (sodium carbonate addition).
[0129] Dissolved oxygen (pO2)
[0130] The concentration of dissolved oxygen is maintained constant at 25% ± 2% of air saturation with air, nitrogen and oxygen flows. The relative ratios of these three different gases are controlled by the fermentation management software through the gas mixer device of the bioreactor. Partial pressure of each: 0,95 atmospheres of oxygen, nitrogen and air.
[0131] Aeration and mixing
[0132] The cell culture was aerated by a ring sparger diffusion system. The gas mixture came out of the sparger located on the base of the fermentation vessel through a 1 mm hole. The bubbles were pushed downward by a stirring system (single marine impeller) to increase the contact time of the gas mixture with the cell culture, thereby improving gas solubility. During the first 24 hours of fermentation, the impeller rotated at 88 rpm ± 5, and then the rate was increased to 100 rpm ± 5 until the cell culture was harvested. During the first 24 hours of each fermentation cycle, the gas flow (gas mixture flow rate) set point was 1,0 ≤ flow rate ≤ 1,3 slpm ± 0,05, and then the value was increased to 1,3 ≤ flow rate ≤ 1,5 slpm ± 0,05 until the cell culture was harvested.
[0133] Semi-continuous fermentation and harvest volume
[0134] After inoculation with the initial working volume of 27L with the rolling bottle collection from upstream 1 (stage A), the fermentation process begins.During each fermentation cycle, feed supplement (5% of total initial volume) is used to feed cell culture at the 1st, 3rd and 5th day, as described in upstream 2 (stage B) part.Regulate glucose concentration to reach the glucose concentration of 4g / L in bioreactor.Periodically interrupt fermentation to carry out the intermediate harvest of cell culture after 6-7 days, harvest the cell culture of about 30L, replace fresh medium to obtain the cell concentration within the range of 100.000-200.000 viable cells / ml at the beginning of each new fermentation cycle.According to the vigor and production requirements of cell culture, carry out at least 3 times and up to 7 split cycles.During fermentation, aseptic sampling is carried out to cell culture every day.At the end of the 3rd, 4th, 5th, 6th or 7th cycle, stop fermentation process and harvest the whole cell cultures in bioreactor. Therefore, the complete fermentation process lasted a total of 27 to 48 days, including equipment washing and sterilization. A total of seven harvests could be obtained from each bioreactor, with a total crude harvest volume of about 215 L / bioreactor. An average of 8 g of crude product was obtained from one fermentation run.
[0135] Microfiltration
[0136] The harvested material was clarified and sterilized using disposable cartridge filters. The first step of clarification was performed using 0.65 μm, 0.6 μm 2 Cartridge filtration is performed, while further clarification and sterilization is performed by a combination of 0.22 μm, 0.45 μm 2 The filtrate is obtained by a cartridge filter. The harvested material is loaded into the filter with a peristaltic pump at a flow rate of 1-2 L / min. The process yield is typically >90%. After filtration, a 0.5 M EDTA solution (pH 8.0) is added to the clarified harvest to obtain a final EDTA concentration of 5 mM. The pH of the raw material is adjusted to 7.5 to obtain a clarified batch of material. The clarified batch of material can be stored at 2-8 ° C for up to two months until the next purification step.
[0137] 1.1.2 Downstream methods
[0138] The downstream process for purifying L19-TNFα includes a series of chromatography and (diafiltration) filtration steps. According to the following scheme, the process is divided into downstream 1 (stage C) and downstream 2 (stage D):
[0139] a) Protein A affinity chromatography (downstream 1)
[0140] b) Gel filtration (for buffer exchange) (downstream 2)
[0141] c) Cation Exchange Chromatography (CIEX) (Downstream 2)
[0142] d) Gel filtration (for buffer exchange / formulation) (downstream 2)
[0143] e) Anion Exchange Chromatography (AIEX) (Downstream 2)
[0144] f) Nanofiltration (for virus removal) (downstream 2)
[0145] g) Diafiltration (for concentration) (downstream 2)
[0146] h) Add Tween 20 (for formulation completion) (downstream 2).
[0147] Downstream 1 (Phase C)
[0148] The downstream 1 process (stage C) consists of an affinity chromatography step using rmp protein A agarose fast flow (recombinant multi-point ligand protein A resin). Multiple chromatography runs are performed to process the entire amount of clarified bulk material obtained at the end of the upstream process. The semi-processed material is then purified in the downstream 2 process at the end of this step or otherwise stored at -80°C for up to 60 days after the addition of 1.5% w / v glycerol. The purification scheme of downstream 1 is shown below.
[0149]
[0150] Buffer preparation
[0151] Each buffer was prepared in a stainless steel tank under mechanical stirring and the pH was adjusted with 5M NaOH or 5M HCl. The buffer was then sterilized by filtration and transferred to a sterile bag or bottle with the help of a peristaltic pump. The buffer was stored at 2-8°C and used within one month.
[0152] Affinity chromatography on protein A (steps from D1-10 to D1-50)
[0153] Protein A affinity chromatography was performed using rmp agarose fast flow resin packed in a Vantage A2-180 column. The resin is a low leakage, non-mammalian based affinity resin designed for high purity separation of monoclonal and polyclonal antibodies. The base matrix (Agarose 4 Fast Flow) is a highly cross-linked 4% agarose derivative containing five antigen binding domains. The scFv (L19) portion of the L19-TNFα fusion protein binds to the protein A immobilized on the resin. The volume of resin packed in the Vantage A2-180 column varies according to the table below.
[0154] column Minimum volume Maximum volume Vantage A2-180 800ml 2000ml
[0155] The volume of resin depends on the amount of sample to be purified; typically 1 ml of resin is used to purify up to 4.3 mg of L19-TNFα.
[0156] Column disinfection and equilibration
[0157] Prior to sample loading, the columns, resins and flow lines of the chromatography system were sterilized in situ with a solution of 0.1 M acetic acid / 20% ethanol. The contact time was at least 60 minutes. After sterilization, the system was equilibrated with 2CV PBS pH 7.50 (50 mM NaH2PO4·2H2O; NaCl 150 mM, 5 mM EDTA, 50 mM NaOH) at a flow rate between 85 and 255 ml / min (corresponding to 20 and 60 cm / h).
[0158] Sample loading
[0159] After disinfection, each run was loaded with a clarified batch of approximately 80 L fractions containing approximately 3800-4300 mg of L19-TNFα. Loading was performed at room temperature at a flow rate between 100 and 200 ml / min (corresponding to 24 and 48 cm / h), which allowed a contact time of at least 8 minutes. Sample loading lasted approximately 14 hours.
[0160] Sample purification
[0161] Once the clarified bulk was loaded, the column was washed sequentially with the following buffers:
[0162] -10CV PBS / NaCl (50mM NaH2PO4·2H2O; 650mM NaCl, 5mM EDTA, 53mM NaOH, pH7.50);
[0163] -5CV PBS pH 7.50 (50mM NaH2PO4·2H2O; 150mM NaCl, 5mM EDTA, 50mM NaOH).
[0164] The L19-TNFα fusion protein was then eluted from the column with 10 mM TEA pH 11.50 (10 mM TEA, 5 mM EDTA, pH 11.50). The sample eluted in a single fraction ranging between 4 and 5 CV. The typical yield of this chromatography step was above 90%. By monitoring A 280nm , conductivity and pH for chromatographic run. The eluted sample (semi-processed material) was then dissolved in 10 mM TEA pH 11.50 (10 mM TEA, 5 mM EDTA, pH 11.50) and incubated at room temperature for 1 hour for viral inactivation. The OD (A280nm ) ranges between 0.470 and 1.460.
[0165] The semi-processed material was either processed in the next purification step in the downstream 2 process or stored at -80°C for a maximum period of 60 days after addition of 1.5% w / v glycerol.
[0166] Downstream 2 (Phase D)
[0167] The downstream 2 process (stage D) consists of a series of chromatography and (diafiltration) filtration steps to purify and refine L19-TNFα. The purified bulk material obtained at the end of the process represents the drug substance. The purification scheme of downstream 2 is shown below.
[0168] Step No. Step Description D2-10 Sephadex G25 System Preparation D2-20 Buffer exchange of semi-processed material over Sephadex G25 (1st run) D2-30 Buffer exchange of semi-processed material over Sephadex G25 (2nd run) D2-40 Buffer exchange of semi-processed material by Sephadex G25 (3rd run) D2-50 CHT II 40μm System Preparation D2-60 Cation exchange of desalinated semi-processed materials by CHT Type II 40 μm D2-70 Formulation of purified intermediate 1 on Sephadex G25 D2-80 Anion exchange of purified intermediate 2 by Sartobind Q D2-90 Nanofiltration of purified intermediate 3 by Viresolve ProModus D2-100 Concentration of purified intermediate 4 using the Sartocon slice cassette system D2-110 Add 0.01% v / v Tween20
[0169] Gel filtration (buffer exchange) through Sephadex G25 (steps D2-10 to D2-40)
[0170] System Preparation
[0171] The semi-processed material (obtained from Downstream 1) was subjected to buffer exchange by gel filtration using cross-linked Sephadex G25 fine resin packed in a Vantage A2-130 column. The volume of resin packed in the Vantage A2-130 column was varied according to the table below.
[0172] column Minimum volume Maximum volume Vantage A2-130 3000ml 4500ml
[0173] The volume of resin used depends on the amount of protein to be processed; typically 1 ml of resin is used to purify up to 0.55 mg of L19-TNFα.
[0174] Column disinfection and equilibration
[0175] Prior to sample loading, the columns, resins and flow lines of the chromatography system were sterilized in situ with a solution of 0.2 M NaOH. After sterilization, the system was equilibrated with 2 CV of a 5 mM phosphate buffer solution (5 mM NaH2PO4·2H2O, pH 6.50) at a flow rate between 100 and 300 ml / min (corresponding to 45 and 135 cm / h).
[0176] Sample loading
[0177] After sterilization, the semi-processed material is loaded at a flow rate between 100 and 300 ml / min (corresponding to 45 and 135 cm / h). The semi-processed material is loaded in several fractions (usually 3-4 fractions) so that the loading does not exceed the capacity of the column (20% of the column volume).
[0178] Sample elution
[0179] L19-TNFα was eluted with 0.6 CV of "5 mM phosphate buffer" solution (5 mM NaH2PO4.2H2O, pH 6.50) at a flow rate between 100 and 300 ml / min (corresponding to 45 and 135 cm / h) (as desalted semi-processed material). Buffer exchange by gel filtration involves approximately 2-3 times dilution. The typical yield of this chromatography step is 65%-80%. By monitoring A 280nm , conductivity and pH for chromatographic runs. The desalted semi-processed material can be stored at 2-8°C for a period of up to 72 hours.
[0180] Cation exchange chromatography (CIEX) (steps from D2-50 to D2-60)
[0181] System Preparation
[0182] Cation exchange chromatography (CIEX) was performed using CHT II ceramic hydroxyapatite (40 μm) resin packed in a Vantage A2-60 column. Multiple groups of five calcium doublets (C sites) and multiple pairs of hydroxyl phosphate triplets (P sites) were arranged in a repeating geometric pattern. The volume of resin packed in the column was varied according to the table below.
[0183] column Minimum volume Maximum volume Vantage A2-60 500ml 1000ml
[0184] The volume of resin used depends on the amount of sample to be purified; typically 1 ml of resin is used to purify up to 2.7 mg of L19-TNFα.
[0185] Column disinfection and equilibration
[0186] Prior to sample loading, the columns, resins and flow lines of the chromatography system were sanitized with a solution of 1 M NaOH. The contact time was at least 60 minutes. After sanitization, the system was equilibrated with 10 CV of "Phosphate Buffer A" solution (10 mM NaH2PO4·2H2O, pH 6.50) at a flow rate between 95 and 235 ml / min (corresponding to 200 and 500 cm / h). A Sartobind Q cartridge (0.250 m 2 Filtration area). Sartobind Q cartridges were activated with 1 M NaCl alone, sanitized with 1 M NaOH (at least 60 min), and equilibrated with a "5 mM phosphate buffer" solution (5 mM NaH2PO4·2H2O, pH 6.50).
[0187] Sample loading
[0188] After column sanitization, the desalted semi-processed material was loaded onto a Sartobind Q-CHT column. Loading was performed at a flow rate between 95 and 235 ml / min (corresponding to 200 and 500 cm / h), which allowed a contact time with the CHT resin of at least 2.5 minutes.
[0189] Sample elution
[0190] After loading, the CHT column was washed with 2CV of "phosphate buffer A" solution (10 mM NaH2PO4·2H2O, pH 6.50). The L19-TNFα fusion protein was then eluted from the column by a linear gradient obtained by gradually introducing 40CV of "phosphate buffer B" solution (10 mM NaH2PO4·2H2O, 1 M NaCl, pH 6.50) from 0 to 100% at a flow rate of 200 ml / min. The typical yield of this chromatography step is about 70%. By monitoring A 280nm , conductivity and pH. The purity of the purified intermediate 1 obtained at the end of the cation exchange chromatography was higher than 98% for total L19-TNFα and higher than 95% for L19-TNFα homotrimer. The purified intermediate 1 can be stored at 2-8°C for a period of up to 48 hours.
[0191] Gel filtration through Sephadex G25 (buffer exchange / formulation) (step D2-70)
[0192] System Preparation
[0193] The third operation step of downstream 2 is the preparation of purified intermediate 1, which is carried out by buffer exchange by gel filtration chromatography. Purified intermediate 1 is treated to transfer fusion protein L19-TNFα to its preparation buffer. Gel filtration is carried out using cross-linked dextran Sephadex G25 fine resin filled in Vantage A2-130 column. The volume of the resin filled in Vantage A2-130 column changes according to the following table.
[0194] column Minimum volume Maximum volume Vantage A2-130 3000ml 4500ml
[0195] The volume of resin used depends on the amount of protein to be processed; typically 1 ml of resin is used to purify up to approximately 0.30 mg of L19-TNFα.
[0196] Column disinfection and equilibration
[0197] Before sample loading, the column, resin and flow line of the chromatography system were sterilized in situ with a solution of 0.2M NaOH. The contact time was at least 60 minutes. After sterilization, the system was balanced with 2CV "formulation buffer L19-TNFα without Tween20" (15mM NaH2PO4·2H2O, 10mM Na2HPO4·2H2O, 1.5mM KCl, 75mM mannitol, 30mM NaCl, 1% w / v glycerol, 5mM EDTA, pH 8.00) at a flow rate between 100 and 300ml / min (corresponding to 45 and 135cm / h).
[0198] Sample loading
[0199] After sterilization, the purified intermediate 1 was loaded at a flow rate between 100 and 300 ml / min (corresponding to 45 and 135 cm / h). The purified intermediate 1 was loaded in several fractions (usually 5 fractions) because the loading should not exceed the capacity of the column (30% of the column volume). Elution was performed after loading each fraction.
[0200] Sample elution
[0201] L19-TNFα was eluted as purified intermediate 2 with 0.6 CV of "formulation buffer L19-TNFα without Tween20" (15 mM NaH2PO4·2H2O, 10 mM Na2HPO4·2H2O, 1.5 mM KCl, 75 mM mannitol, 30 mM NaCl, 1% w / v glycerol, 5 mM EDTA, pH 8.00) at a flow rate between 150 and 250 ml / min (corresponding to 70 and 113 cm / h). Buffer exchange by gel filtration included about 1.5-fold dilution. The typical yield of this chromatography step was about 95%. The whole process usually lasted about 2 hours. By monitoring A 280nm , conductivity and pH were used for the chromatographic run. The purified intermediate 2 was then directly processed in the next purification step of anion exchange chromatography.
[0202] Anion exchange chromatography (AIEX) by Sartobind Q (step D2-80)
[0203] The ion exchange chromatography (AIEX) was performed using 0.250 m 2Disposable Sartobind Q capsules with a filter area of 100 μl were used to treat purified intermediate 2. Before sample loading, the capsules were activated by flushing with 200 ml NaCl 1M; the capsules were then sterilized by flushing with NaOH 1M for at least 60 minutes and equilibrated by flushing with "Tween20-free formulation buffer L19-TNFα" (15 mM NaH2PO4·2H2O, 10 mM Na2HPO4·2H2O, 1.5 mM KCl, 75 mM mannitol, 30 mM NaCl, 1% w / v glycerol, 5 mM EDTA, pH 8.00) at a flow rate between 150 and 300 ml / min. Purified intermediate 2 was loaded at a flow rate between 150 and 250 ml / min. L19-TNFα protein is positively charged (pH 8.0), so Sartobind Q capsules were used in flow-through mode and L19-TNFα was collected directly into a container as purified intermediate 3. Possible negatively charged contaminants (such as residual DNA) are removed by binding to the Sartobind O matrix. Typical yields for this chromatography step are above 95%. Purified intermediate 3 can be stored at 2-8°C for a period of up to 48 hours before the next purification step by nanofiltration.
[0204] Nanofiltration (removal of viruses) (step D2-90)
[0205] Intermediate 3 was purified by nanofiltration to remove viruses using either a Viresolve ProModus 1.1 or Viresolve ProModus 1.2 filter. ProModus 1.1 or 1.2 can be used, with filter areas of 0.017 and 0.070 m, respectively. 2. The nominal membrane cutoff is about 20 nm. Before use, the column is wetted by flushing water for injection at a constant pressure of 1.8 bar for 10 minutes, and then disinfected by flushing 0.5M NaOH at the same pressure for at least 60 minutes. After disinfection, the column is balanced by flushing with "formulation buffer L19-TNFα without Tween20" (15mM NaH2PO4·2H2O, 10mM Na2HPO4·2H2O, 1.5mM KCl, 75mM mannitol, 30mM NaCl, 1% w / v glycerol, 5mM EDTA, pH 8.00) at a constant pressure of 3 bar for 5 minutes. After equilibrium, the purified intermediate 3 is loaded at a flow rate of about 300ml / min (for Viresolve ProModus 1.2 filter). The recovery rate of L19-TNFα after nanofiltration is generally higher than 99%. At the end of nanofiltration, purified intermediate 4 is obtained. If the optical density is below 0.530, the purified intermediate 4 is concentrated in the next downstream 2 step. Otherwise, 0.01% v / v Tween 20 is added directly to it to complete the drug substance formulation to obtain the purified bulk material.
[0206] Diafiltration (for concentration) (step D2-100)
[0207] If the optical density is lower than 0.530, the purified intermediate 4 is concentrated by diafiltration to adjust its optical density to a suitable range contained between 0.530 and 0.580. The Sartocon Slice box system is used for diafiltration. The system is sterilized by circulating 1M NaOH for at least 60 minutes, then rinsed with water for injection and balanced with "formulation buffer L19-TNFα without Tween20" (15mM NaH2PO4·2H2O, 10mM Na2HPO4·2H2O, 1.5mM KCl, 75mM mannitol, 30mM NaCl, 1% w / v glycerol, 5mM EDTA, pH 8.00) at a flow rate of about 50ml / min. When the balance is complete, the purified intermediate 4 is loaded into the system. The purified intermediate 4 is continuously rinsed through the Sartocon box. L19-TNFα is retained and returned to the starting bottle "retentate", while the formulation buffer that passes through the membrane is discarded in the bottle "permeate". Since the buffer is not replaced, the concentration of L19-TNFα gradually increases. During the concentration process, the volume of purified intermediate 4 is reduced by about 2-4 times depending on the starting optical density. The process is controlled by monitoring the optical density value. When it reaches the established range of 0.530-0.580, the concentration process is stopped. The yield of this operation step is generally higher than 99%. 0.01% v / v Tween20 can then be added directly to the purified intermediate 5 obtained to complete the drug substance preparation.
[0208] Add 0.01% v / v Tween20 (step D2-110)
[0209] The drug substance formulation is obtained by adding 0.01% v / v Tween20. A stock solution of 10% v / v Tween20 is added in an appropriate amount to reach a final content of 0.01% v / v Tween20. If the optical density is already in the range of 0.530-0.580, Tween20 is added to the purified intermediate 4 at the end of nanofiltration, otherwise it is added to the purified intermediate 5 after the concentration process is completed. The addition of 0.01% v / v Tween20 completes the downstream 2 process. The purified batch material (drug substance) can be stored at 2-8°C for a period of up to 7 days, or at -80°C for up to 1 month.
[0210] Example 2 - Quality Control of GMP Batches
[0211] Several quality control analyses including ELISA, SDS-PAGE, size exclusion chromatography, A 280 The purity of the good manufacturing practice (GMP) batch prepared according to Example 1 was characterized by HPLC (HPLC, HPLC, HPLC-MS / MS, HPLC-MS / MS, etc.), productivity, bioactivity and immunoreactivity assays, osmolality, virus testing, visual appearance, etc. The protocol used for 2D-SDS-PAGE analysis is reported below.
[0212] 2.1 2D-SDS-PAGE
[0213] Use prefabricated systems ( IPGRunner TM ) Each sample was analyzed in a two-dimensional electrophoresis assay. The assay was performed by using two pH ranges for isoelectric focusing:
[0214] 1) pH 3.0-10.0
[0215] 2) pH 6.0-10.0.
[0216] In (1), the pH range is broad enough to highlight the final contaminants, while in (2), the pH range is less separated but still includes the isoelectric point of the sample (pH = 7.7). Staining was performed with blue Coomassie R-250. The results are reported in Figure 3.
[0217] Example 3 - Mass spectrometry analysis of GMP batches
[0218] 3.1 Direct Infusion HR-MS for Intact Mass Analysis
[0219] 100 μg of L19-TNFα sample was desalted with C18-purification (micro spin columns, Harvard Apparatus) before analysis. Direct infusion was performed on an Orbitrap Q-Exactive coupled to an Ion Max ESI source. The following parameters were used: syringe flow rate 4 μL / min, capillary voltage 3.0 kV, in-source induced dissociation 40 eV, sheath gas 4 units, capillary temperature 300°C, S-lens RF level 90, resolution 17500 (FWHM at 200 m / z), AGC target 5×10 4 , microscan 10, mass range 500-3000 m / z, and maximum injection time 200 ms. The raw spectra were then analyzed to quantify the relative amounts of glycosylated and non-glycosylated L19-TNFα in the formulation to the total L19-TNFα. Quantification was achieved by summing the intensities of the peaks corresponding to glycosylated or non-glycosylated L19-TNFα, respectively, and the percentages were calculated using the following equation.
[0220]
[0221] where x is the sum of the intensities corresponding to non-glycosylated or glycosylated L19-TNFα, respectively. The results of this analysis are shown in Figure 4 and Figure 5.
[0222] 3.2 MS / MS analysis for glycopeptide analysis
[0223] 7.5 μg of L19-TNFα was resuspended in 1M urea (dissolved in NH4HCO3 solution), and the final pH was 8. The protein was reduced with TCEP for 15 min at room temperature, then reduced at 65 ° C for 45 min, and alkylated with iodoacetamide (IAA) for 1 hour in the dark. L19-TNFα was then digested with trypsin (enzyme-protein ratio 1: 60) at 37 ° C overnight. After digestion, the sample was acidified with 10% formic acid and then subjected to C18 purification and desalting (small centrifugal column, Harvard Apparatus). 500ng of the resulting peptide was then subjected to HPLC-MS / MS analysis. All samples were analyzed on an Orbitrap Q-Exactive mass spectrometer, which was coupled to an EASY nanoLC 1000 system via a Nano Flex ion source. Chromatographic separation was performed on an AcclaimPepMap RSLC column (50 μm x 15 cm, particle size 2 μm, pore size ) with a 40 min linear gradient of 5%-35% solvent B (0.1% formic acid in acetonitrile) at a flow rate of 300 nL / min. Ionization was performed in positive ion mode with a spray voltage of 2 kV, a capillary temperature of 250°C, and an S-lens RF level of 60. The mass spectrometer was operated in data dependent mode. The MS1 scan range was set from 350 to 1650 m / z, and the 10 most abundant peptides were subjected to HCD fragmentation with an NCE of 25. Dynamic exclusion was set to 10 seconds. The raw files were processed with Proteome Discoverer 1.4. Database searches were performed using Sequest as the search engine using FASTA files containing the target protein, the mus musculus reference proteome, and additional contaminants (human keratin isoforms, bovine serum albumin, and protein A from Staphylococcus Aureus). Carbamidomethylation of cysteine was set as a fixed modification, while oxidation and O-glycosylation (HexNAc1Hex1NeuAc1) of methionine were set as variable modifications. Trypsin was set as cleavage specificity, allowing up to 2 missed cleavages. Data filtering was performed using a percolator, resulting in a 1% false discovery rate (FDR). The results of this analysis are reported in Figure 6 and Figure 7 middle.
[0224] Sequence Listing
[0225] Amino acid sequence of L19 CDR
[0226] L19 CDR1 VH-SFSMS (SEQ ID NO:1)
[0227] L19 CDR2 VH-SISGSSGTTYYADSVKG (SEQ ID NO:2)
[0228] L19 CDR3 VH-PFPYFDY (SEQ ID NO:3)
[0229] L19 CDR1 VL-RASQSVSSSFLA (SEQ ID NO:4)
[0230] L19 CDR2 VL-YASSRAT (SEQ ID NO:5)
[0231] L19 CDR3 VL-QQTGRIPPT (SEQ ID NO:6)
[0232] Amino acid sequence of L19 VH domain (SEQ ID NO: 7)
[0233] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
[0234] Amino acid sequence of the linker between VH and VL (SEQ ID NO: 8)
[0235] GDGSSGGSGGAS
[0236] Amino acid sequence of L19 VL domain (SEQ ID NO: 9)
[0237] EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
[0238] Amino acid sequence of L19 scFv (SEQ ID NO: 10)
[0239] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS GDGSSGGSGGAS EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
[0240] Amino acid sequence of the soluble form of the extracellular domain of human TNFα (huTNFα) (SEQ ID NO: 11) 。
[0241]
[0242] Amino acid sequence of the linker between scFv and TNFα (SEQ ID NO: 12)
[0243] EFSSSSGSSSSGSSSSG
[0244] Amino acid sequence of L19-huTNFα conjugate (SEQ ID NO: 13)
[0245] Serine 257 is shown in bold, italic and underlined
[0246]
[0247] Amino acid sequence of L19-IL2 conjugate (SEQ ID NO: 14)
[0248] Threonine 256 is shown in bold, italic and underlined
[0249]
[0250]
Claims
1. A pharmaceutical preparation, comprising: (i) non-glycosylated L19-TNFα; and (ii) glycosylated L19-TNFα; The L19-TNFα comprises or consists of the sequence shown in SEQ ID NO: 13, and the percentage of glycosylated L19-TNFα in the total L19-TNFα in the preparation is ≤6%. 2 . The pharmaceutical formulation according to claim 1 , wherein the glycosylated L19-TNFα comprises O-linked glycosylation on the serine at position 257 of SEQ ID NO:
13.
3. The pharmaceutical formulation according to claim 2, wherein the O-linked glycosylation consists of HexNAc1Hex1NeuAc1.
4. The pharmaceutical formulation according to any one of claims 1 to 3, wherein the percentage of glycosylated L19-TNFα is determined by mass spectrometry analysis, preferably by intact mass spectrometry analysis.
5. The pharmaceutical preparation according to any one of claims 1 to 4, further comprising a pharmaceutically acceptable excipient, a carrier, a buffer, a stabilizer.
6. The pharmaceutical formulation according to any one of claims 1 to 5, for use in a method of treating cancer in a patient.
7. The pharmaceutical formulation for use according to claim 6, wherein the cancer is melanoma, glioma or skin cancer, such as malignant melanoma or non-melanoma skin cancer.
8. The pharmaceutical formulation for use according to claim 6 or 7, wherein the method comprises administering a second anti-cancer therapeutic agent to the patient.
